Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IDE161 in Advanced Solid Tumors
NCT05787587Phase 1Active, not recruiting
- Sponsor
- IDEAYA Biosciences
- Start
- Apr 2023
- Primary completion
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of IDE161 in solid tumor, breast cancer, ovarian cancer and 6 more (4 arms), sponsored by IDEAYA Biosciences. Primary endpoints: Maximum Tolerated Dose at 2 years, Recommended Dose for Expansion at 2 years and 2 more. Started Apr 2023; status: active, not recruiting.
02
Drugs
IDE161
03
Conditions
solid tumorbreast cancerovarian cancerprostate cancer (PCa)endometrial cancer (EC)
Beyond the preview
Go deeper on NCT05787587.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05787587.